**BREAKING NEWS: September 12, 2024**

BREAKING NEWS: September 12, 2024

WASHINGTON, D.C. — A new pharmaceutical product marketed under the name “Trumprx” has entered clinical trials in the United States, according to an official announcement from the Food and Drug Administration (FDA) on Wednesday.

WHAT: The FDA confirmed receipt of an Investigational New Drug application for “Trumprx,” described by its manufacturer as a novel therapeutic compound intended to address age-related metabolic decline.

WHO: The drug is developed by Cortex Biolabs Inc., a privately held biotechnology firm headquartered in Austin, Texas. Former President Donald J. Trump has publicly endorsed the company’s mission but holds no formal role in its operations or financial holdings, per a statement from his office.

WHEN: The first phase of human trials commenced on September 10, 2024, at research hospitals in Houston and Cleveland.

WHERE: The trials are being conducted across two FDA-approved sites, with plans to expand to six additional locations in the Northeast and Midwest by the first quarter of 2025.

WHY: Company executives claim the drug targets a specific cellular repair mechanism linked to inflammation and energy production. Federal regulators emphasized that the trials are in their earliest stage, with safety and efficacy data expected no sooner than late 2025.

CONTEXT: Public interest surged hours after the announcement, generating over 2 million social media mentions. Financial analysts report a 340% increase in trading volume for Cortex Biolabs’ private shares on secondary markets.

The FDA reiterated that no conclusions about the product’s safety or effectiveness can be drawn at this time.